A man known as “The Crooked Man” has spent more than 300 days training only one trapezius muscle to deliberately reject ...
“This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...
Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...
Around the world, 10.6 percent of people are left-handed. Handedness is a form of so-called functional brain asymmetry: left-right differences in brain function. In left-handers, the right motor ...
The shape of the universe is not something we often think about. My colleagues and I have published a new study that suggests it could be asymmetric or lopsided, meaning not the same in every ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved aficamten to improve functional capacity and symptoms in adults with obstructive hypertrophic ...
Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. The ...
Dec 19 (Reuters) - The U.S. Food and Drug Administration has approved Cytokinetics' (CYTK.O), opens new tab oral drug to treat a rare heart condition, the company said on Friday. The keenly watched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback